News and Trends 4 Sep 2024
2024: a year of breakthroughs for endometrial cancer?
New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs.
Antibody-drug conjugates
- Latest Posts
Podcast 21 Jun 2024
How ADCs can deliver death cap mushroom toxins to treat cancer
Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101.
Best in Biotech 8 Feb 2024
Fourteen biotech companies spearheading the antibody drug conjugate industry
The antibody-drug conjugate market has gained significant traction recently. Discover some of the top ADC companies in the industry.
News and Trends 20 Nov 2023
M&As: what’s up with the ADC buying spree?
Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]
In Depth 13 Oct 2023
How close are we to a cure for metastatic breast cancer?
Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […]
News and Trends 27 Jul 2023
Epsilogen completes first clinical trial of IgE antibody to treat cancer
Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 26 Jul 2023
Antibody drug conjugates: BiVictriX drives a new era in cancer medicine
The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black box warning after patients experienced adverse side effects, and there had been fatalities. But this didn’t discourage biopharmas looking to create safer alternatives from expediting […]
Podcast 7 Jul 2023
Beyond Biotech podcast 53: Antibody-drug conjugates
On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs, antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink, […]
News and Trends 1 Jun 2023
Lonza boosts ADC portfolio with Synaffix acquisition
Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […]
News and Trends 28 Apr 2023
ADC firm Adcentrx Therapeutics aims for clinic after $38M boost
Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx’s financial advisors. Adcentrx Therapeutics intends to use the […]
News and Trends 20 Apr 2023
FDA approves Genentech’s lymphoma drug
Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The approval covers the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell […]
News and Trends 14 Apr 2023
TORL BioTherapeutics launches with $158M to target cancer
TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered in the laboratory of scientific co-founder Dennis Slamon, professor of medicine, and chief of […]
ADVERTISEMENT
